Stem definition | Drug id | CAS RN |
---|---|---|
1285 | 25812-30-0 |
Dose | Unit | Route |
---|---|---|
1.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.02 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 79.89 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 98 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 21, 1981 | FDA | PFIZER PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rhabdomyolysis | 224.26 | 13.05 | 123 | 10030 | 38904 | 50556067 |
Drug hypersensitivity | 72.44 | 13.05 | 157 | 9996 | 250853 | 50344118 |
Blood triglycerides increased | 57.66 | 13.05 | 33 | 10120 | 11279 | 50583692 |
Coronary artery disease | 54.02 | 13.05 | 46 | 10107 | 29680 | 50565291 |
Myocardial infarction | 46.38 | 13.05 | 72 | 10081 | 88955 | 50506016 |
Blood creatine phosphokinase increased | 46.27 | 13.05 | 40 | 10113 | 26327 | 50568644 |
Acute interstitial pneumonitis | 42.91 | 13.05 | 12 | 10141 | 611 | 50594360 |
Cardiac failure congestive | 35.51 | 13.05 | 62 | 10091 | 84320 | 50510651 |
Myopathy | 34.52 | 13.05 | 22 | 10131 | 9117 | 50585854 |
Cerebrovascular accident | 32.83 | 13.05 | 64 | 10089 | 94616 | 50500355 |
Myalgia | 31.54 | 13.05 | 74 | 10079 | 124245 | 50470726 |
Pancreatitis | 30.32 | 13.05 | 40 | 10113 | 42574 | 50552397 |
Pancreatitis acute | 28.11 | 13.05 | 29 | 10124 | 23783 | 50571188 |
Drug interaction | 27.26 | 13.05 | 95 | 10058 | 199526 | 50395445 |
Lip infection | 23.66 | 13.05 | 5 | 10148 | 76 | 50594895 |
Blood glucose increased | 23.26 | 13.05 | 47 | 10106 | 71277 | 50523694 |
Diabetes mellitus | 21.89 | 13.05 | 37 | 10116 | 48996 | 50545975 |
Off label use | 21.54 | 13.05 | 39 | 10114 | 474387 | 50120584 |
Drug intolerance | 20.75 | 13.05 | 9 | 10144 | 219095 | 50375876 |
Drug ineffective | 20.45 | 13.05 | 90 | 10063 | 819243 | 49775728 |
Tendon rupture | 19.35 | 13.05 | 14 | 10139 | 7130 | 50587841 |
Bursitis | 17.66 | 13.05 | 22 | 10131 | 22113 | 50572858 |
Microalbuminuria | 16.47 | 13.05 | 5 | 10148 | 340 | 50594631 |
Synovitis | 15.53 | 13.05 | 3 | 10150 | 123862 | 50471109 |
Hypertriglyceridaemia | 15.42 | 13.05 | 11 | 10142 | 5480 | 50589491 |
Chronic kidney disease | 15.15 | 13.05 | 28 | 10125 | 39743 | 50555228 |
Blood urea increased | 15.04 | 13.05 | 21 | 10132 | 23564 | 50571407 |
Angioedema | 14.95 | 13.05 | 27 | 10126 | 37649 | 50557322 |
Hyperlipidaemia | 14.95 | 13.05 | 18 | 10135 | 17472 | 50577499 |
Infusion related reaction | 14.47 | 13.05 | 8 | 10145 | 169549 | 50425422 |
Transient ischaemic attack | 13.97 | 13.05 | 24 | 10129 | 32186 | 50562785 |
Myositis | 13.86 | 13.05 | 12 | 10141 | 7908 | 50587063 |
Hypophagia | 13.82 | 13.05 | 22 | 10131 | 27706 | 50567265 |
Blood creatine phosphokinase MB increased | 13.82 | 13.05 | 6 | 10147 | 1136 | 50593835 |
Diabetes mellitus inadequate control | 13.72 | 13.05 | 15 | 10138 | 13130 | 50581841 |
Granulocytopenia | 13.60 | 13.05 | 10 | 10143 | 5221 | 50589750 |
Glaucoma | 13.17 | 13.05 | 16 | 10137 | 15670 | 50579301 |
Joint swelling | 13.16 | 13.05 | 18 | 10135 | 245268 | 50349703 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rhabdomyolysis | 540.34 | 13.20 | 349 | 14268 | 60459 | 29499451 |
Acute kidney injury | 112.77 | 13.20 | 336 | 14281 | 264931 | 29294979 |
Blood creatine phosphokinase increased | 107.81 | 13.20 | 116 | 14501 | 40528 | 29519382 |
Myalgia | 95.86 | 13.20 | 148 | 14469 | 73871 | 29486039 |
Blood triglycerides increased | 95.06 | 13.20 | 66 | 14551 | 12768 | 29547142 |
Coronary artery disease | 71.16 | 13.20 | 98 | 14519 | 44092 | 29515818 |
Myocardial infarction | 58.71 | 13.20 | 152 | 14465 | 110144 | 29449766 |
Drug hypersensitivity | 56.17 | 13.20 | 112 | 14505 | 68294 | 29491616 |
Polymyositis | 52.45 | 13.20 | 21 | 14596 | 1307 | 29558603 |
Blood cholesterol increased | 47.55 | 13.20 | 48 | 14569 | 15547 | 29544363 |
Off label use | 45.63 | 13.20 | 49 | 14568 | 300751 | 29259159 |
Cardiac failure congestive | 44.32 | 13.20 | 109 | 14508 | 76472 | 29483438 |
Drug interaction | 40.06 | 13.20 | 198 | 14419 | 197187 | 29362723 |
Pancreatitis | 36.44 | 13.20 | 63 | 14554 | 34451 | 29525459 |
Myopathy | 29.54 | 13.20 | 31 | 14586 | 10502 | 29549408 |
International normalised ratio increased | 28.71 | 13.20 | 66 | 14551 | 44306 | 29515604 |
Drug ineffective | 27.64 | 13.20 | 90 | 14527 | 363080 | 29196830 |
Thunderclap headache | 27.10 | 13.20 | 6 | 14611 | 43 | 29559867 |
Hyperglycaemia | 25.58 | 13.20 | 54 | 14563 | 34233 | 29525677 |
Drug level below therapeutic | 24.87 | 13.20 | 19 | 14598 | 4252 | 29555658 |
Chromaturia | 24.61 | 13.20 | 31 | 14586 | 12771 | 29547139 |
Drug abuse | 24.19 | 13.20 | 5 | 14612 | 79878 | 29480032 |
Haemodialysis | 23.91 | 13.20 | 27 | 14590 | 9927 | 29549983 |
Chronic kidney disease | 23.37 | 13.20 | 54 | 14563 | 36362 | 29523548 |
Granulocytopenia | 23.10 | 13.20 | 21 | 14596 | 5973 | 29553937 |
Blood glucose increased | 22.31 | 13.20 | 72 | 14545 | 58912 | 29500998 |
Death | 20.68 | 13.20 | 93 | 14524 | 341991 | 29217919 |
Type 2 diabetes mellitus | 20.17 | 13.20 | 29 | 14588 | 13552 | 29546358 |
Myositis | 19.92 | 13.20 | 25 | 14592 | 10258 | 29549652 |
Product use in unapproved indication | 19.91 | 13.20 | 9 | 14608 | 86866 | 29473044 |
Angioedema | 19.04 | 13.20 | 46 | 14571 | 31869 | 29528041 |
Angina unstable | 18.84 | 13.20 | 25 | 14592 | 10840 | 29549070 |
General physical health deterioration | 18.83 | 13.20 | 14 | 14603 | 102843 | 29457067 |
Blood glucose decreased | 18.26 | 13.20 | 26 | 14591 | 12043 | 29547867 |
Erosive duodenitis | 18.05 | 13.20 | 10 | 14607 | 1297 | 29558613 |
Tricuspid valve incompetence | 17.22 | 13.20 | 21 | 14596 | 8373 | 29551537 |
Reversible cerebral vasoconstriction syndrome | 16.99 | 13.20 | 6 | 14611 | 263 | 29559647 |
Pyrexia | 16.88 | 13.20 | 79 | 14538 | 287543 | 29272367 |
Treatment noncompliance | 16.74 | 13.20 | 37 | 14580 | 24190 | 29535720 |
Lacrimation decreased | 16.55 | 13.20 | 3 | 14614 | 6 | 29559904 |
Fanconi syndrome | 16.18 | 13.20 | 10 | 14607 | 1588 | 29558322 |
Muscular weakness | 16.07 | 13.20 | 67 | 14550 | 61985 | 29497925 |
Hypertriglyceridaemia | 15.82 | 13.20 | 19 | 14598 | 7456 | 29552454 |
Pneumonia haemophilus | 15.60 | 13.20 | 6 | 14611 | 335 | 29559575 |
Blood creatinine increased | 15.54 | 13.20 | 83 | 14534 | 85019 | 29474891 |
Asthenia | 15.28 | 13.20 | 168 | 14449 | 215082 | 29344828 |
Otitis externa | 14.98 | 13.20 | 8 | 14609 | 965 | 29558945 |
Interstitial lung disease | 14.84 | 13.20 | 5 | 14612 | 57713 | 29502197 |
Arteriosclerosis coronary artery | 14.81 | 13.20 | 22 | 14595 | 10583 | 29549327 |
Hyperlipidaemia | 14.63 | 13.20 | 24 | 14593 | 12566 | 29547344 |
Breast neoplasm | 14.31 | 13.20 | 3 | 14614 | 16 | 29559894 |
Metabolic acidosis | 14.26 | 13.20 | 46 | 14571 | 37616 | 29522294 |
Coronary artery stenosis | 13.76 | 13.20 | 19 | 14598 | 8554 | 29551356 |
Renal tubular necrosis | 13.64 | 13.20 | 25 | 14592 | 14290 | 29545620 |
Hyperlactacidaemia | 13.62 | 13.20 | 11 | 14606 | 2667 | 29557243 |
Aortic valve sclerosis | 13.51 | 13.20 | 7 | 14610 | 793 | 29559117 |
Chest pain | 13.41 | 13.20 | 98 | 14519 | 111875 | 29448035 |
Paralysis | 13.35 | 13.20 | 15 | 14602 | 5482 | 29554428 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rhabdomyolysis | 707.11 | 12.63 | 410 | 20062 | 91316 | 64386944 |
Blood creatine phosphokinase increased | 157.60 | 12.63 | 138 | 20334 | 58420 | 64419840 |
Blood triglycerides increased | 157.36 | 12.63 | 89 | 20383 | 18777 | 64459483 |
Coronary artery disease | 134.43 | 12.63 | 128 | 20344 | 60305 | 64417955 |
Acute kidney injury | 125.71 | 12.63 | 369 | 20103 | 448871 | 64029389 |
Myocardial infarction | 117.49 | 12.63 | 198 | 20274 | 165623 | 64312637 |
Myalgia | 110.51 | 12.63 | 188 | 20284 | 158429 | 64319831 |
Drug hypersensitivity | 88.13 | 12.63 | 217 | 20255 | 237598 | 64240662 |
Cardiac failure congestive | 75.80 | 12.63 | 143 | 20329 | 130437 | 64347823 |
Drug interaction | 66.89 | 12.63 | 259 | 20213 | 361824 | 64116436 |
Off label use | 62.98 | 12.63 | 65 | 20407 | 632741 | 63845519 |
Pancreatitis | 58.75 | 12.63 | 83 | 20389 | 59524 | 64418736 |
Myopathy | 58.54 | 12.63 | 47 | 20425 | 17633 | 64460627 |
Drug ineffective | 50.59 | 12.63 | 121 | 20351 | 840126 | 63638134 |
Polymyositis | 46.97 | 12.63 | 21 | 20451 | 2689 | 64475571 |
Granulocytopenia | 41.65 | 12.63 | 31 | 20441 | 10409 | 64467851 |
Hyperlipidaemia | 37.12 | 12.63 | 41 | 20431 | 22935 | 64455325 |
Myositis | 36.97 | 12.63 | 35 | 20437 | 16342 | 64461918 |
Hyperglycaemia | 35.62 | 12.63 | 67 | 20405 | 60901 | 64417359 |
Chromaturia | 34.22 | 12.63 | 39 | 20433 | 22572 | 64455688 |
Blood glucose increased | 32.60 | 12.63 | 86 | 20386 | 97987 | 64380273 |
Acute interstitial pneumonitis | 31.37 | 12.63 | 12 | 20460 | 1035 | 64477225 |
International normalised ratio increased | 31.11 | 12.63 | 74 | 20398 | 79093 | 64399167 |
Chronic kidney disease | 30.59 | 12.63 | 61 | 20411 | 57858 | 64420402 |
Blood cholesterol increased | 30.47 | 12.63 | 56 | 20416 | 50010 | 64428250 |
Hypertriglyceridaemia | 29.29 | 12.63 | 26 | 20446 | 11179 | 64467081 |
Angioedema | 29.00 | 12.63 | 62 | 20410 | 61759 | 64416501 |
Drug intolerance | 28.48 | 12.63 | 12 | 20460 | 187980 | 64290280 |
Muscular weakness | 28.42 | 12.63 | 97 | 20375 | 127241 | 64351019 |
Blood creatinine increased | 28.20 | 12.63 | 101 | 20371 | 135681 | 64342579 |
Treatment failure | 26.56 | 12.63 | 3 | 20469 | 116813 | 64361447 |
Pyrexia | 26.47 | 12.63 | 90 | 20382 | 558554 | 63919706 |
Drug abuse | 26.41 | 12.63 | 5 | 20467 | 132369 | 64345891 |
Pancreatitis acute | 26.16 | 12.63 | 48 | 20424 | 42807 | 64435453 |
Haemodialysis | 25.07 | 12.63 | 29 | 20443 | 17048 | 64461212 |
Cerebrovascular accident | 24.15 | 12.63 | 97 | 20375 | 137486 | 64340774 |
Blood glucose decreased | 23.96 | 12.63 | 33 | 20439 | 23090 | 64455170 |
Angina unstable | 23.95 | 12.63 | 27 | 20445 | 15440 | 64462820 |
General physical health deterioration | 23.86 | 12.63 | 18 | 20454 | 204407 | 64273853 |
Renal failure | 23.53 | 12.63 | 117 | 20355 | 181571 | 64296689 |
Type 2 diabetes mellitus | 23.20 | 12.63 | 40 | 20432 | 33980 | 64444280 |
Hypoglycaemia | 22.30 | 12.63 | 71 | 20401 | 89821 | 64388439 |
Acute myocardial infarction | 21.02 | 12.63 | 59 | 20413 | 69659 | 64408601 |
Thunderclap headache | 20.63 | 12.63 | 6 | 20466 | 220 | 64478040 |
Joint swelling | 20.36 | 12.63 | 23 | 20449 | 215359 | 64262901 |
Erosive duodenitis | 19.86 | 12.63 | 10 | 20462 | 1668 | 64476592 |
Infusion related reaction | 19.81 | 12.63 | 14 | 20458 | 164453 | 64313807 |
Coronary artery stenosis | 19.79 | 12.63 | 21 | 20451 | 11227 | 64467033 |
Treatment noncompliance | 19.69 | 12.63 | 43 | 20429 | 43439 | 64434821 |
Cardiac disorder | 19.62 | 12.63 | 50 | 20422 | 55766 | 64422494 |
Lip infection | 18.99 | 12.63 | 5 | 20467 | 126 | 64478134 |
Chest pain | 18.93 | 12.63 | 134 | 20338 | 235846 | 64242414 |
Arteriosclerosis coronary artery | 18.93 | 12.63 | 24 | 20448 | 15505 | 64462755 |
High density lipoprotein decreased | 18.67 | 12.63 | 13 | 20459 | 3933 | 64474327 |
Rheumatoid arthritis | 18.49 | 12.63 | 15 | 20457 | 164279 | 64313981 |
C-reactive protein increased | 18.07 | 12.63 | 4 | 20468 | 94905 | 64383355 |
Renal cyst | 17.87 | 12.63 | 21 | 20451 | 12549 | 64465711 |
Blood urea increased | 17.05 | 12.63 | 41 | 20431 | 44112 | 64434148 |
Bursitis | 16.98 | 12.63 | 27 | 20445 | 21458 | 64456802 |
Intervertebral disc displacement | 16.78 | 12.63 | 6 | 20466 | 428 | 64477832 |
Metabolic acidosis | 16.65 | 12.63 | 55 | 20417 | 70903 | 64407357 |
Hypophagia | 16.63 | 12.63 | 38 | 20434 | 39549 | 64438711 |
Fanconi syndrome | 16.13 | 12.63 | 10 | 20462 | 2491 | 64475769 |
Tricuspid valve incompetence | 15.75 | 12.63 | 23 | 20449 | 16980 | 64461280 |
Blood creatine phosphokinase MB increased | 15.70 | 12.63 | 10 | 20462 | 2611 | 64475649 |
Product use issue | 15.69 | 12.63 | 15 | 20457 | 151700 | 64326560 |
Hyperkalaemia | 15.18 | 12.63 | 68 | 20404 | 101061 | 64377199 |
Condition aggravated | 15.01 | 12.63 | 64 | 20408 | 372362 | 64105898 |
Myoglobinuria | 14.97 | 12.63 | 7 | 20465 | 993 | 64477267 |
Coronary artery occlusion | 14.66 | 12.63 | 20 | 20452 | 13871 | 64464389 |
Hypercholesterolaemia | 14.54 | 12.63 | 21 | 20451 | 15352 | 64462908 |
Carotid artery stenosis | 14.28 | 12.63 | 15 | 20457 | 7926 | 64470334 |
Ischaemic cardiomyopathy | 14.27 | 12.63 | 14 | 20458 | 6824 | 64471436 |
Product complaint | 13.82 | 12.63 | 18 | 20454 | 11936 | 64466324 |
Tendon rupture | 13.70 | 12.63 | 17 | 20455 | 10750 | 64467510 |
Acute coronary syndrome | 13.55 | 12.63 | 23 | 20449 | 19287 | 64458973 |
Product use in unapproved indication | 13.51 | 12.63 | 22 | 20450 | 176596 | 64301664 |
Diabetes mellitus | 13.41 | 12.63 | 49 | 20423 | 66425 | 64411835 |
Maternal exposure during pregnancy | 13.16 | 12.63 | 7 | 20465 | 95877 | 64382383 |
Erectile dysfunction | 13.05 | 12.63 | 18 | 20454 | 12609 | 64465651 |
Aspartate aminotransferase increased | 12.67 | 12.63 | 73 | 20399 | 119715 | 64358545 |
None
Source | Code | Description |
---|---|---|
ATC | C10AB04 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Fibrates |
FDA CS | M0199111 | PPAR alpha |
FDA MoA | N0000175375 | Peroxisome Proliferator-activated Receptor alpha Agonists |
FDA EPC | N0000175596 | Peroxisome Proliferator Receptor alpha Agonist |
CHEBI has role | CHEBI:35679 | antilipemic drugs |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D065687 | Cytochrome P-450 CYP2C8 Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D000960 | Hypolipidemic Agents |
MeSH PA | D057847 | Lipid Regulating Agents |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertriglyceridemia | indication | 302870006 | |
Primary Prevention of Coronary Heart Disease | indication | ||
Hypoalphalipoproteinemia | off-label use | 190785000 | |
Primary biliary cirrhosis | contraindication | 31712002 | DOID:12236 |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Acute nephropathy | contraindication | 58574008 | |
Leukopenia | contraindication | 84828003 | DOID:615 |
Impaired renal function disorder | contraindication | 197663003 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Calculus in biliary tract | contraindication | 266474003 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 5.13 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Peroxisome proliferator-activated receptor alpha | Nuclear hormone receptor | AGONIST | EC50 | 4.23 | IUPHAR | CHEMBL | |||
Transthyretin | Secreted | Kd | 7 | CHEMBL | |||||
Cytochrome P450 2C8 | Enzyme | Ki | 5.74 | WOMBAT-PK | |||||
Lipoprotein lipase | Enzyme | WOMBAT-PK | |||||||
CDGSH iron-sulfur domain-containing protein 1 | Unclassified | Ki | 5.14 | CHEMBL | |||||
Cytochrome P450 2C9 | Enzyme | Ki | 4.52 | WOMBAT-PK | |||||
Fatty acid-binding protein, liver | Unclassified | Ki | 5.73 | CHEMBL |
ID | Source |
---|---|
4018639 | VUID |
N0000146952 | NUI |
D00334 | KEGG_DRUG |
4018639 | VANDF |
C0017245 | UMLSCUI |
CHEBI:5296 | CHEBI |
4TX | PDB_CHEM_ID |
CHEMBL457 | ChEMBL_ID |
DB01241 | DRUGBANK_ID |
D015248 | MESH_DESCRIPTOR_UI |
3463 | PUBCHEM_CID |
3439 | IUPHAR_LIGAND_ID |
3899 | INN_ID |
Q8X02027X3 | UNII |
4719 | RXNORM |
4778 | MMSL |
523 | MMSL |
d00245 | MMSL |
002050 | NDDF |
35282000 | SNOMEDCT_US |
387189002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Lopid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0071-0737 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9130 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9707 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8354 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 15 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-569 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | Human Prescription Drug Label | 1 | 16571-784 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 15 sections |
Gemfibrozil | Human Prescription Drug Label | 1 | 16714-101 | TABLET | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-732 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24658-260 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-128 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-225 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-146 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-260 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-745 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-745 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-921 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-090 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-772 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 21 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43602-452 | TABLET | 600 mg | ORAL | ANDA | 10 sections |
Gemfibrozil | Human Prescription Drug Label | 1 | 50090-2450 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 15 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2902 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5808 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-350 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51138-588 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51655-142 | TABLET | 600 mg | ORAL | ANDA | 9 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51655-143 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-1068 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | Human Prescription Drug Label | 1 | 53002-2068 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 15 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53217-251 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0251 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |